Welcome to our dedicated page for Hookipa Pharma SEC filings (Ticker: HOOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HOOKIPA Pharma Inc. filings document public-company status changes for its common stock, governance actions, and material events. Form 25 records the voluntary withdrawal of the common stock from Nasdaq listing and Section 12(b) registration, while Form 15 records termination or suspension provisions under the Exchange Act for the same security class.
The filing record also includes 8-K disclosure on a special stockholder meeting, proxy-referenced vote matters, registered security details, and corporate-status disclosures associated with asset-sale and dissolution-related proposals.
Malte Peters, CEO and director of HOOKIPA Pharma Inc. (HOOK), reported an insider sale. On 08/19/2025 he disposed of 25,172 shares of the issuer's common stock for a weighted average price of $0.8217 per share. Following the transactions he beneficially owns 54,347 shares. The Form 4 notes the sale occurred in multiple transactions at prices ranging from $0.8205 to $0.8225 and offers to provide a breakdown of the number of shares sold at each price on request. The filing is signed by Malte Peters on 10/09/2025.
HOOKIPA Pharma Inc. filed a Form 144/A reporting a proposed sale of 25,172 shares of common stock to be executed on 08/19/2025 through Maxim Group on the NASDAQ. The filing lists an aggregate market value of $20,155 for the shares and shows 9,789,622 shares outstanding.
The securities were acquired as restricted stock units on 07/22/2024 (amount: 54,347) and the notice states the intended payment is compensation. The filing also discloses a recent sale on 07/23/2025 of 29,176 shares for $26,911. The signer represents no undisclosed material adverse information about the issuer.
HOOKIPA Pharma (HOOK) Form 4: On 22 Jul 2025, Chief Executive Officer and Director Malte Peters sold 29,176 common shares at $0.92 per share (≈ $26.8k proceeds). The sale was executed under a pre-arranged “sell-to-cover” program to satisfy tax-withholding obligations triggered by the vesting of RSUs granted on 22 Jul 2024; therefore it was not a discretionary trade. After the transaction, Peters holds 79,519 shares, all owned directly.
No derivative securities were bought or sold, and no additional corporate developments were disclosed. The filing is routine insider-ownership maintenance rather than a signal of changed outlook, but investors may note the reduced float at the margin.